A consortium of China-based pharmaceutical companies, potentially including the state-owned giant Sinopharm (HKG: 1099), is reportedly considering the acquisition of Poland-based drug wholesaler Neuca. According to sources, the potential sale was discussed during a recent consultation between Neuca and Poland’s Competition and Consumer Office UOKIK. However, no specifics regarding the potential price or timeline have been disclosed.
Strategic Move into the European Market
The acquisition of Neuca is seen as a strategic move by state-backed Chinese entities to gain a foothold in the European market. Established in 1992, Neuca is the leading pharmaceutical wholesaler in Poland, responsible for procuring over 30% of the country’s medicines and medical supplies. The company generated revenues of over USD 2.8 billion in 2022 and employs nearly 5,000 people.
Concerns Over Drug Supply Security in Poland
Critics of the deal in Poland have raised concerns that the acquisition may threaten Poland’s drug supply security. The potential takeover by Chinese entities has sparked debates over the implications for the country’s pharmaceutical industry and the potential impact on the security and stability of its drug supply chain.-Fineline Info & Tech
